Markets:

Overview

News

Currencies

International

Treasuries

Erasca, Inc. - Common Stock (NQ:ERAS)

6.760 +0.950 (+16.35%)

Streaming Delayed Price Updated: 4:00 PM EST, Jan 9, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Erasca, Inc. - Common Stock

< Previous 1 2 3 4 Next >

Benzinga's Top Ratings Upgrades, Downgrades For February 24, 2023 ↗

February 24, 2023

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For February 3, 2023 ↗

February 03, 2023

Via Benzinga

Erasca Touts Promising Early Data From Lead Cancer Programs ↗

September 08, 2022

Via Benzinga

12 Health Care Stocks Moving In Thursday's After-Market Session ↗

January 12, 2023

Via Benzinga

Over $4 Million Bet On Werewolf Therapeutics? Check Out These 4 Penny Stocks Insiders Are Buying ↗

January 11, 2023

The Dow Jones closed higher on Tuesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks...

Via Benzinga

Stocks That Hit 52-Week Lows On Tuesday ↗

January 10, 2023

Tuesday's session saw 16 companies set new 52-week lows.

Via Benzinga

Erasca to Present at the 41st Annual J.P. Morgan Healthcare Conference

January 04, 2023

From Erasca, Inc.

Via GlobeNewswire

Red Cat Holdings And 2 Other Penny Stocks Insiders Are Aggressively Buying ↗

December 27, 2022

The Dow Jones settled higher by around 175 points on Friday. Investors, meanwhile, focused on some notable insider trades. When insiders purchase or sell shares, it indicates their confidence or...

Via Benzinga

Erasca Announces First Patient Dosed in HERKULES-1 Phase 1b Trial Evaluating ERAS-007 and ERAS-601 MAPKlamp Combination in RAS/MAPK Pathway-Altered Solid Tumors

December 20, 2022

From Erasca, Inc.

Via GlobeNewswire

12 Health Care Stocks Moving In Monday's After-Market Session ↗

December 19, 2022

Via Benzinga

Erasca Announces FDA Clearance of IND Application for CNS-Penetrant KRAS G12C Inhibitor ERAS-3490 in KRAS G12C-Mutated Advanced or Metastatic Solid Tumors

December 13, 2022

ERAS-3490, an orally available small molecule KRAS G12C inhibitor, has demonstrated robust nonclinical CNS and systemic activity

From Erasca, Inc.

Via GlobeNewswire

RH, HUYA, Bilibili And Some Other Big Stocks Moving Lower On Monday ↗

December 12, 2022

U.S. stocks traded higher, with the Dow Jones jumping more than 200 points on Monday. Here are some big stocks recording losses in today’s session.

Via Benzinga

Why Ambrx Biopharma Shares Are Trading Higher By Over 550%? Here Are 52 Stocks Moving In Friday's Mid-Day Session ↗

December 09, 2022

Gainers Ambrx Biopharma Inc. (NYSE: AMAM) shares jumped 551.4% to $2.67 after the company announced preliminary Phase 2 results from its ACE-Breast-03 study showing a 57.1% overall response rate.

Via Benzinga

12 Health Care Stocks Moving In Friday's Intraday Session ↗

December 09, 2022

Via Benzinga

Lululemon, Li Auto, Hackett Group And Some Other Big Stocks Moving Lower On Friday ↗

December 09, 2022

U.S. stocks traded lower, with the Dow Jones jumping around 70 points on Friday. Here are some big stocks recording losses in today’s session.

Via Benzinga

Erasca Oulicenses Its Mid-Stage Cancer Program To Novartis, Raises $100M Via Equity Offering ↗

December 09, 2022

Via Benzinga

Erasca Announces Exclusive Worldwide License for Pan-RAF Inhibitor Naporafenib

December 09, 2022

From Erasca, Inc.

Via GlobeNewswire

Erasca Announces Pricing of Underwritten Offering of Common Stock

December 09, 2022

From Erasca, Inc.

Via GlobeNewswire

Erasca Announces Clinical Trial Collaboration and Supply Agreement with Pierre Fabre to Evaluate ERAS-007 and Encorafenib Combination

November 30, 2022

From Erasca, Inc.

Via GlobeNewswire

Erasca to Present at Upcoming Investor Conferences

November 22, 2022

From Erasca, Inc.

Via GlobeNewswire

Erasca Reports Third Quarter 2022 Financial Results and Business Updates

November 09, 2022

From Erasca, Inc.

Via GlobeNewswire

Erasca Announces Clinical Trial Collaboration and Supply Agreement with Pfizer to Evaluate ERAS-007 and Palbociclib Combination

October 20, 2022

From Erasca, Inc.

Via GlobeNewswire

McCormick, Dave & Buster's Entertainment And Other Big Losers From Thursday ↗

September 09, 2022

U.S. stocks closed higher with the Dow Jones surging around 193 points on Thursday. Here is the list of some big stocks moving lower in the previous session.

Via Benzinga

Why ShiftPixy Surged Around 177%; Here Are 71 Biggest Movers From Yesterday ↗

September 09, 2022

Gainers ShiftPixy, Inc. (NASDAQ: PIXY) shares surged 176.5% to close at $31.00 on Thursday after the company announced plans to spin-off ShiftPixy Labs and dividend its digital securities to...

Via Benzinga

US Stocks Flat, Crude Oil Rises 2% ↗

September 08, 2022

U.S. stocks traded almost flat in volatile trading on Thursday following the release of jobless claims data.

Via Benzinga

Peering Into Erasca's Recent Short Interest ↗

September 08, 2022

Erasca's (NASDAQ:ERAS) short percent of float has fallen 17.88% since its last report. The company recently reported that it has 15.10 million shares sold short, which is 19.57%...

Via Benzinga

Why Bilibili Is Trading Lower By Over Around 14%, Here Are 50 Stocks Moving In Thursday's Mid-Day Session ↗

September 08, 2022

Gainers ShiftPixy, Inc. (NASDAQ: PIXY) shares jumped 73.8% to $19.48 after the company announced plans to spin-off ShiftPixy Labs and dividend its digital securities to shareholders.

Via Benzinga

US Stocks Turn Higher, Nasdaq Jumps 100 Points ↗

September 08, 2022

U.S. stocks turned higher midway through trading, with the Nasdaq Composite gaining around 100 points on Thursday.

Via Benzinga

Important Biotech Catalysts For September 7, 2022 - End Of The Day Summary ↗

September 07, 2022

Via Benzinga

Why Embark Technology Jumped Around 85%; Here Are 108 Biggest Movers From Friday ↗

August 15, 2022

Gainers Embark Technology, Inc. (NASDAQ: EMBK) jumped 84.8% to close at $1.07 on Friday after the company reported better-than-expected Q2 EPS results.

Via Benzinga

< Previous 1 2 3 4 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.